Anti-Human CEACAM-5/CD66e Reference Antibody (Tusamitamab, RUO)

Description: Tusamitamab (BS10731) is a research-grade recombinant antibody targeting CD66. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Chimeric
Isotype: IgG1-Kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Meconiumantigen100,CEACAM5,CEA,CD66e,Carcinoembryonicantigen-relatedcelladhesionmolecule5,Carcinoembryonicantigen
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: SAR-408377,CAS:2349294-95-5
Background: Cell adhesion molecule CEACAM5 (CD66e) is a ~76 kDa protein. Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling and tumor progression. Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6. Plays a role as an oncogene by promoting tumor progression; induces resistance to anoikis of colorectal carcinoma cells.
References:
1. Taheri, M. et al. (2000) The Journal of biological chemistry 275, 26935-43. PMID: 10864933
2. Ordoñez, C. et al. (2000) Cancer research 60, 3419-24. PMID: 1091005
3. Oikawa, S. et al. (1989) Biochemical and biophysical research communications 164, 39-45. PMID: 2803308
Note: For research use only. Not suitable for clinical or therapeutic use.